Szabolcs Farkas Selected Research

4- cyano- 1- (2- iodophenyl)- 5- (4- methoxyphenyl)- N- (piperidin- 1- yl)- 1H- pyrazole- 3- carboxamide

4/2012	The decrease of dopamine D₂/D₃ receptor densities in the putamen and nucleus caudatus goes parallel with maintained levels of CB₁ cannabinoid receptors in Parkinson's disease: a preliminary autoradiographic study with the selective dopamine D₂/D₃ antagonist [³H]raclopride and the novel CB₁ inverse agonist [¹²⁵I]SD7015.
2/2012	[¹²⁵I]SD-7015 reveals fine modalities of CB₁ cannabinoid receptor density in the prefrontal cortex during progression of Alzheimer's disease.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Szabolcs Farkas Research Topics

Disease

2	Parkinson Disease (Parkinson's Disease) 05/2012 - 04/2012
1	Alzheimer Disease (Alzheimer's Disease) 02/2012
1	Stroke (Strokes) 09/2010

Drug/Important Bio-Agent (IBA)

2	Dopamine Receptors (Dopamine Receptor)IBA 05/2012 - 04/2012
2	RacloprideIBA 05/2012 - 04/2012
2	Dopamine (Intropin)FDA LinkGeneric 05/2012 - 04/2012
2	Cannabinoid Receptors (Cannabinoid Receptor)IBA 04/2012 - 02/2012
2	4- cyano- 1- (2- iodophenyl)- 5- (4- methoxyphenyl)- N- (piperidin- 1- yl)- 1H- pyrazole- 3- carboxamideIBA 04/2012 - 02/2012
1	LigandsIBA 02/2012
1	A-factor (Streptomyces)IBA 02/2012
1	PotassiumIBA 09/2010